Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae

Introduction Occurrence of colistin-resistant Enterobacteriaceae in response to the unregulated use of this antibiotic has been documented. This study reports an investigation of colistin resistance rates among carbapenem-resistant enterobacterial clinical isolates.Methods A total of 196 multidrug-r...

Full description

Bibliographic Details
Main Authors: Hadir A. El-Mahallawy, Marwa El Swify, Asmaa Abdul Hak, Mai M. Zafer
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Annals of Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2022.2129775
_version_ 1798015318735454208
author Hadir A. El-Mahallawy
Marwa El Swify
Asmaa Abdul Hak
Mai M. Zafer
author_facet Hadir A. El-Mahallawy
Marwa El Swify
Asmaa Abdul Hak
Mai M. Zafer
author_sort Hadir A. El-Mahallawy
collection DOAJ
description Introduction Occurrence of colistin-resistant Enterobacteriaceae in response to the unregulated use of this antibiotic has been documented. This study reports an investigation of colistin resistance rates among carbapenem-resistant enterobacterial clinical isolates.Methods A total of 196 multidrug-resistant Enterobacteriaceae isolates (Klebsiella pneumoniae (n = 100), Escherichia coli (n = 89) and Enterobacter cloacae (n = 7) were selected from Gram-negative isolates over one year. Susceptibility to antimicrobials was determined using Vitek2. Broth microdilution method was used to detect colistin antimicrobial susceptibility. Identification of ESBL and carbapenemases were both done phenotypically and by PCR.Results All the studied isolates showed multidrug-resistant phenotypes with 51.5% resistance to carbapenems (meropenem, imipenem). Very low resistance rates towards tigecycline (n = 9) 4.6% were found. Thirty-nine isolates (19.9%) showed reduced susceptibility to colistin among the MDR isolates. Sixty-four isolates (32.7%) were ESBL producers. Hundred isolates (51%) were carbapenemase producers using Carba NP test. The PCR amplification results revealed that 40 isolates (20%) harboured NDM-1 and 40 isolates contained OXA-48-like gene. Coexistence of both (NDM-1 and OXA-48-like) was observed in nine (4.59%) isolates. A Statistically significant relationship was observed between carbapenem resistance and each of the followings; OXA-48 producers (p= .009), amikacin resistance (p = .000), gentamicin resistance (p = .032), tobramycin resistance (p = .000), and tigecycline resistance (p-value ≤ .001). A statistical significance was detected between ESBL-producing isolates and carbapenem susceptible isolates ESBL producers with p = 0.000.Conclusion An alarming sign is the increasing colistin resistance rates among carbapenem-resistant isolates. Aminoglycosides are still a therapeutic option to decrease the use of colistin and avoid further development of resistance.KEY MESSAGESHigh rates of colistin resistance among carbapenem-resistant Enterobacteriaceae.The choice of antibiotic is significantly associated with the clinical site of infection.Aminoglycosides are offered choices for treating multiple drug-resistant Enterobacteriaceae to preserve the colistin and carbapenems.
first_indexed 2024-04-11T15:31:22Z
format Article
id doaj.art-803c94002a3f4b8f831bd70575e5f320
institution Directory Open Access Journal
issn 0785-3890
1365-2060
language English
last_indexed 2024-04-11T15:31:22Z
publishDate 2022-12-01
publisher Taylor & Francis Group
record_format Article
series Annals of Medicine
spelling doaj.art-803c94002a3f4b8f831bd70575e5f3202022-12-22T04:16:07ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602022-12-015411910.1080/07853890.2022.2129775Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant EnterobacteriaceaeHadir A. El-Mahallawy0Marwa El Swify1Asmaa Abdul Hak2Mai M. Zafer3Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, EgyptDepartment of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, EgyptDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Cairo, EgyptDepartment of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Cairo, EgyptIntroduction Occurrence of colistin-resistant Enterobacteriaceae in response to the unregulated use of this antibiotic has been documented. This study reports an investigation of colistin resistance rates among carbapenem-resistant enterobacterial clinical isolates.Methods A total of 196 multidrug-resistant Enterobacteriaceae isolates (Klebsiella pneumoniae (n = 100), Escherichia coli (n = 89) and Enterobacter cloacae (n = 7) were selected from Gram-negative isolates over one year. Susceptibility to antimicrobials was determined using Vitek2. Broth microdilution method was used to detect colistin antimicrobial susceptibility. Identification of ESBL and carbapenemases were both done phenotypically and by PCR.Results All the studied isolates showed multidrug-resistant phenotypes with 51.5% resistance to carbapenems (meropenem, imipenem). Very low resistance rates towards tigecycline (n = 9) 4.6% were found. Thirty-nine isolates (19.9%) showed reduced susceptibility to colistin among the MDR isolates. Sixty-four isolates (32.7%) were ESBL producers. Hundred isolates (51%) were carbapenemase producers using Carba NP test. The PCR amplification results revealed that 40 isolates (20%) harboured NDM-1 and 40 isolates contained OXA-48-like gene. Coexistence of both (NDM-1 and OXA-48-like) was observed in nine (4.59%) isolates. A Statistically significant relationship was observed between carbapenem resistance and each of the followings; OXA-48 producers (p= .009), amikacin resistance (p = .000), gentamicin resistance (p = .032), tobramycin resistance (p = .000), and tigecycline resistance (p-value ≤ .001). A statistical significance was detected between ESBL-producing isolates and carbapenem susceptible isolates ESBL producers with p = 0.000.Conclusion An alarming sign is the increasing colistin resistance rates among carbapenem-resistant isolates. Aminoglycosides are still a therapeutic option to decrease the use of colistin and avoid further development of resistance.KEY MESSAGESHigh rates of colistin resistance among carbapenem-resistant Enterobacteriaceae.The choice of antibiotic is significantly associated with the clinical site of infection.Aminoglycosides are offered choices for treating multiple drug-resistant Enterobacteriaceae to preserve the colistin and carbapenems.https://www.tandfonline.com/doi/10.1080/07853890.2022.2129775Carbapenem-resistant Enterobacteriaceaeaminoglycosidestigecyclinecolistin resistancecarbapenemase geneshealthcare-associated infections
spellingShingle Hadir A. El-Mahallawy
Marwa El Swify
Asmaa Abdul Hak
Mai M. Zafer
Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
Annals of Medicine
Carbapenem-resistant Enterobacteriaceae
aminoglycosides
tigecycline
colistin resistance
carbapenemase genes
healthcare-associated infections
title Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
title_full Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
title_fullStr Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
title_full_unstemmed Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
title_short Increasing trends of colistin resistance in patients at high-risk of carbapenem-resistant Enterobacteriaceae
title_sort increasing trends of colistin resistance in patients at high risk of carbapenem resistant enterobacteriaceae
topic Carbapenem-resistant Enterobacteriaceae
aminoglycosides
tigecycline
colistin resistance
carbapenemase genes
healthcare-associated infections
url https://www.tandfonline.com/doi/10.1080/07853890.2022.2129775
work_keys_str_mv AT hadiraelmahallawy increasingtrendsofcolistinresistanceinpatientsathighriskofcarbapenemresistantenterobacteriaceae
AT marwaelswify increasingtrendsofcolistinresistanceinpatientsathighriskofcarbapenemresistantenterobacteriaceae
AT asmaaabdulhak increasingtrendsofcolistinresistanceinpatientsathighriskofcarbapenemresistantenterobacteriaceae
AT maimzafer increasingtrendsofcolistinresistanceinpatientsathighriskofcarbapenemresistantenterobacteriaceae